2.37
-0.11 (-4.44%)
| Previous Close | 2.48 |
| Open | 2.44 |
| Volume | 751,778 |
| Avg. Volume (3M) | 1,217,211 |
| Market Cap | 154,957,440 |
| Price / Sales | 12.61 |
| Price / Book | 1.03 |
| 52 Weeks Range | |
| Earnings Date | 31 Mar 2026 |
| Operating Margin (TTM) | -500.53% |
| Diluted EPS (TTM) | -0.910 |
| Quarterly Revenue Growth (YOY) | 10.30% |
| Total Debt/Equity (MRQ) | 4.18% |
| Current Ratio (MRQ) | 5.30 |
| Operating Cash Flow (TTM) | -37.48 M |
| Levered Free Cash Flow (TTM) | -20.36 M |
| Return on Assets (TTM) | -17.89% |
| Return on Equity (TTM) | -30.11% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Medical Devices (US) | Mixed | Bearish |
| Medical Devices (Global) | Mixed | Bearish | |
| Stock | NANO-X IMAGING LTD | Bearish | Bearish |
AIStockmoo Score
| Analyst Consensus | 1.5 |
| Insider Activity | NA |
| Price Volatility | 0.5 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 0.5 |
| Average | 1.25 |
|
Nano X Imaging Ltd is engaged in the business of manufacturing medical imaging systems. It offers a Nanox System which is a combination of hardware and software. It develops a prototype of the Nanox.ARC, a medical imaging system incorporating its novel digital X-ray source; and Nanox.CLOUD, a companion cloud-based software that will allow for the delivery of medical screening as a service. It has three business segments: Nanox.ARC division, the radiology services division and the AI solutions division. Key revenue is generated from Radiology Services. |
|
| Sector | Healthcare |
| Industry | Medical Devices |
| Investment Style | Small Growth |
| % Held by Insiders | 0.23% |
| % Held by Institutions | 24.70% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Griffin Asset Management, Inc. | 31 Dec 2025 | 170,309 |
| 52 Weeks Range | ||
| Median | 5.00 (110.97%) | |
| Total | 1 Buy | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| D. Boral Capital | 03 Mar 2026 | 5.00 (110.97%) | Buy | 2.59 |
| 04 Feb 2026 | 5.00 (110.97%) | Buy | 2.42 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 03 Feb 2026 | Announcement | Nanox Receives FDA 510(k) Clearance for TAP2D New Image Enhancement Capability for Nanox.ARC and Nanox.ARC X Systems |
| 14 Jan 2026 | Announcement | Nanox Expands in Europe with New Nanox.ARC Distribution Engagement in Serbia, Montenegro, and Bosnia and Herzegovina |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |